Applied Therapeutics, Inc.
APLT
$0.10
-$0.01-7.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 719.67% | -- | -- | 100.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 719.67% | -- | -- | 100.00% | -- |
| Cost of Revenue | -35.25% | -0.81% | -35.85% | -23.58% | 37.49% |
| Gross Profit | 41.51% | -0.64% | 34.84% | 26.77% | -36.36% |
| SG&A Expenses | -37.71% | 24.53% | 95.10% | 323.32% | 219.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.49% | 12.21% | 19.93% | 62.34% | 92.74% |
| Operating Income | 39.59% | -13.00% | -21.01% | -57.19% | -91.95% |
| Income Before Tax | 72.31% | -836.02% | 74.00% | 216.79% | -61.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 72.31% | -836.02% | 74.00% | 216.79% | -61.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.31% | -836.02% | 74.00% | 216.79% | -61.89% |
| EBIT | 39.59% | -13.00% | -21.01% | -57.19% | -91.95% |
| EBITDA | 39.59% | -13.00% | -21.02% | -57.19% | -91.95% |
| EPS Basic | 72.54% | -831.34% | 77.50% | 189.35% | -1.69% |
| Normalized Basic EPS | 70.81% | -829.37% | 77.50% | 189.57% | -1.68% |
| EPS Diluted | 72.54% | -15.21% | 77.50% | 188.50% | -1.69% |
| Normalized Diluted EPS | 70.81% | -872.27% | 77.50% | 189.57% | -1.68% |
| Average Basic Shares Outstanding | 0.84% | 0.80% | 15.54% | 30.70% | 59.20% |
| Average Diluted Shares Outstanding | 0.84% | -4.79% | 15.54% | 30.70% | 59.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |